UY37293A - Forma farmacéutica de unidades múltiples que comprende un núcleo con unidades centrales individuales cubiertas por un material muco-adhesivo, y un recubrimiento de núcleo entérico - Google Patents
Forma farmacéutica de unidades múltiples que comprende un núcleo con unidades centrales individuales cubiertas por un material muco-adhesivo, y un recubrimiento de núcleo entéricoInfo
- Publication number
- UY37293A UY37293A UY0001037293A UY37293A UY37293A UY 37293 A UY37293 A UY 37293A UY 0001037293 A UY0001037293 A UY 0001037293A UY 37293 A UY37293 A UY 37293A UY 37293 A UY37293 A UY 37293A
- Authority
- UY
- Uruguay
- Prior art keywords
- core
- muco
- pharmaceutical form
- adhesive material
- understanding
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a una forma farmacéutica de unidades múltiples que comprende un núcleo, donde el núcleo comprende una pluralidad de unidades individuales, donde cada unidad comprende un principio farmacéuticamente activo y cada unidad está cubierta con un material muco-adhesivo, y donde la forma farmacéutica de unidades múltiples comprende, además, una capa de recubrimiento del núcleo. La invención se refiere, además, al uso de dicha forma farmacéutica de unidades múltiples en el tratamiento de trastornos inflamatorios, en especial para el tracto gastrointestinal.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16174466.9A EP3257501A1 (en) | 2016-06-14 | 2016-06-14 | Multiple unit dosage form comprising a core with individual core units covered by a mucoadhesive material, and an enteric core coating |
Publications (1)
Publication Number | Publication Date |
---|---|
UY37293A true UY37293A (es) | 2018-01-02 |
Family
ID=56131433
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001037293A UY37293A (es) | 2016-06-14 | 2017-06-14 | Forma farmacéutica de unidades múltiples que comprende un núcleo con unidades centrales individuales cubiertas por un material muco-adhesivo, y un recubrimiento de núcleo entérico |
Country Status (9)
Country | Link |
---|---|
US (1) | US20190336449A1 (es) |
EP (2) | EP3257501A1 (es) |
JP (1) | JP2019518758A (es) |
AR (1) | AR108729A1 (es) |
CA (1) | CA3026840A1 (es) |
MA (1) | MA45240A (es) |
TW (1) | TW201742621A (es) |
UY (1) | UY37293A (es) |
WO (1) | WO2017216088A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108434109A (zh) * | 2018-04-25 | 2018-08-24 | 首都医科大学附属北京儿童医院 | 微型巯嘌呤片、微型巯嘌呤肠溶缓释片、及其制备方法 |
EP3613414A1 (de) | 2018-08-24 | 2020-02-26 | Dr. Falk Pharma Gmbh | Pellets mit mehrschichtiger struktur zur verzögerten freisetzung des wirkstoffs im distalen kolon |
EP3846784A1 (en) * | 2018-09-06 | 2021-07-14 | Fachhochschule Nordwestschweiz | Controlled drug release formulation |
CN112770730B (zh) * | 2018-09-06 | 2024-02-13 | 瑞士西北应用科学与艺术大学 | 受控的药物释放制剂 |
EP3662901A1 (en) * | 2018-12-07 | 2020-06-10 | Tillotts Pharma AG | Delayed release drug formulation comprising an outerlayer with an enzymaticyaaly degradable polymer, its composition and its method of manufacturing |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA825384B (en) | 1981-07-31 | 1983-05-25 | Tillott J B Ltd | Orally administrable pharmaceutical compositions |
US4627851A (en) | 1984-10-26 | 1986-12-09 | Alza Corporation | Colonic-therapeutic delivery system |
WO2007076874A1 (en) * | 2006-01-05 | 2007-07-12 | Lifecycle Pharma A/S | Disintegrating loadable tablets |
GB0607534D0 (en) | 2006-04-13 | 2006-05-24 | Univ London Pharmacy | Colonic drug delivery formulation |
SI2152250T1 (sl) | 2007-05-07 | 2020-06-30 | Evonik Operations Gmbh | Trdne dozirne oblike, ki vsebujejo enterično oplaščenje s pospešenim sproščanjem zdravila |
GB0808537D0 (en) * | 2008-05-12 | 2008-06-18 | Archimedes Dev Ltd | Compositions |
EP2168572A1 (en) | 2008-09-30 | 2010-03-31 | Omya Development Ag | New controlled release active agent carrier |
PL2264108T3 (pl) | 2009-06-15 | 2012-07-31 | Omya Int Ag | Sposób wytwarzania przereagowanego powierzchniowo węglanu wapnia, z wykorzystaniem słabego kwasu |
RS56839B1 (sr) | 2012-04-30 | 2018-04-30 | Tillotts Pharma Ag | Formulacija leka sa odloženim otpuštanjem |
MX2016001840A (es) | 2013-10-29 | 2016-08-11 | Tillotts Pharma Ag | Formulacion de farmaco de liberacion retardada. |
-
2016
- 2016-06-14 EP EP16174466.9A patent/EP3257501A1/en not_active Ceased
-
2017
- 2017-05-19 TW TW106116604A patent/TW201742621A/zh unknown
- 2017-06-12 EP EP17732814.3A patent/EP3468538A1/en not_active Withdrawn
- 2017-06-12 US US16/310,168 patent/US20190336449A1/en not_active Abandoned
- 2017-06-12 MA MA045240A patent/MA45240A/fr unknown
- 2017-06-12 CA CA3026840A patent/CA3026840A1/en not_active Abandoned
- 2017-06-12 JP JP2018565293A patent/JP2019518758A/ja active Pending
- 2017-06-12 WO PCT/EP2017/064250 patent/WO2017216088A1/en unknown
- 2017-06-14 AR ARP170101621A patent/AR108729A1/es unknown
- 2017-06-14 UY UY0001037293A patent/UY37293A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP3257501A1 (en) | 2017-12-20 |
CA3026840A1 (en) | 2017-12-21 |
MA45240A (fr) | 2019-04-17 |
WO2017216088A1 (en) | 2017-12-21 |
JP2019518758A (ja) | 2019-07-04 |
US20190336449A1 (en) | 2019-11-07 |
AR108729A1 (es) | 2018-09-19 |
EP3468538A1 (en) | 2019-04-17 |
TW201742621A (zh) | 2017-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY37293A (es) | Forma farmacéutica de unidades múltiples que comprende un núcleo con unidades centrales individuales cubiertas por un material muco-adhesivo, y un recubrimiento de núcleo entérico | |
ES2631980T3 (es) | Formas de dosificación orales farmacéuticas que comprenden dabigatrán etexilato y sus sales farmacéuticamente aceptables | |
CL2019001714A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer. | |
CO2017012362A2 (es) | Formas de dosificación sólida que comprenden palbociclib, un ácido hidrosoluble y un portador farmacéuticamente aceptable y métodos para su produccion y uso | |
CO2017011437A2 (es) | Composiciones de nanopartículas para terapia sostenida | |
SV2015005115A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
NI202000099A (es) | Compuestos de purinona y su uso en el tratamiento del cáncer | |
BR112013024585A8 (pt) | formas de dosagem farmacêutica de liberação controlada | |
CL2016000143A1 (es) | Comprimido farmacéutico que comprende ácido acetilsalicílico y clopidogrel | |
CL2016003306A1 (es) | Comprimidos probióticos bicapa de doble liberación | |
CL2019002900A1 (es) | Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton. | |
MX2015009058A (es) | Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias. | |
UY35693A (es) | Pirazolo[1,5-a]piridin-3-carboxamidas sustituidas y su uso | |
CL2018000811A1 (es) | Formulaciones de aminoácidos de liberación modificada administradas por vía oral. | |
UY35344A (es) | Oestra-1,3,5(10),16-tetraeno-3-carboxamidas | |
CY1118327T1 (el) | Χρηση ενος παραγωγου πυραζολιου στην αντιμετωπιση οξεων εξαρσεων χρονιας αποφρακτικης πνευμονοπαθειας | |
UY35455A (es) | Inhibidores tripeptidicos de la epoxicetona proteasa | |
CR20150096A (es) | Formulaciones de trans-clomifeno y usos de los mismas | |
CL2017000845A1 (es) | Inhibidores de gingipaina de lisina | |
BR112012028656A2 (pt) | combinação de grânulos carregados ativos com ativos adicionais | |
BR112015029894A2 (pt) | forma de dosagem farmacêutica sólida | |
CO2018010951A2 (es) | Compuestos de cinnolin-4-amina y su uso en el tratamiento del cáncer | |
AR112701A1 (es) | Método para preparar una forma de dosificación sólida que comprende anticuerpos por granulación en húmedo, extrusión y esferonización | |
ITUA20161615A1 (it) | Dispositivo migliorato multi-dose dinamico per l’erogazione, in forma di gocce, di una soluzione medicinale o un farmaco, in particolare un collirio |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20230626 |